GRL-0617 is a drug which is one of the first compounds discovered that acts as a selective small-molecule inhibitor of the protease enzyme papain-like protease (PLpro) found in some human pathogenic viruses, including the coronavirus SARS-CoV-2.

It has been shown to inhibit viral replication in silico [1] and in vitro.

[2][3][4][5]

This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.